Toxoplasma gondii C2 Domain Protein Deletion Mutant as a Promising Vaccine Against Toxoplasmosis in Mice
Microbial Biotechnology · 2025
DOI: 10.1111/1751-7915.70143 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microbial Biotechnology, 2025. Verfasst von Yifan Luo und 8 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Agricultural Microbiology, College of Veterinary Medicine, Huazhong Agricultural University, Wuhan, Hubei, China. Hauptthemen laut MEDLINE: Toxoplasma, Protozoan Vaccines, Protozoan Proteins, Toxoplasmosis, Animal. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China.
Abstract (Originalsprache)
Toxoplasma gondii ( T. gondii ), a parasitic protozoan capable of infecting nearly all warm‐blooded animals, causes significant economic losses in livestock and poses a significant threat to both animal and public health. Despite its impact, no ideal vaccine is currently available to prevent toxoplasmosis. Vesicular transport plays a crucial role in the life cycle of T. gondii , and proteins involved in this process – such as those containing C2 domains – may serve as novel targets for the development of live attenuated vaccines. In this study, we evaluated the feasibility of a C2 domain‐containing protein (TGME49_203240) as a live attenuated vaccine candidate. Our findings suggest that TGME49_203240 may be involved in vesicular transport and that it is essential for T. gondii growth. Deletion of TGME49_203240 reduced parasite virulence and impaired tissue cyst formation in mice. Moreover, mice vaccinated with ME49 Δ203240 were protected against the lethal challenge of the tachyzoites of T. gondii I, II, III strains and cysts of II strain. In addition, the ME49 Δ203240 strain elicited robust immune responses, including the production of high levels of specific IgG antibodies and key cytokines (IFN‐γ, TNF‐α and IL‐12). These findings highlight TGME49_203240 as a promising target for the development of a live attenuated vaccine against T. gondii .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Agricultural Microbiology, College of Veterinary Medicine, Huazhong Agricultural University, Wuhan, Hubei, China.
- College of Veterinary Medicine, Huazhong Agricultural University, Wuhan, Hubei, China.
ORCID-Profile: Siyu Xiao
Förderung
- National Key Research and Development Program of China
Zitieren
APA
Luo, Y., He, M., Yang, S., Qian, J., He, Z., Xu, J., Guo, L., Xiao, S., & Fang, R. (2025). Toxoplasma gondii C2 Domain Protein Deletion Mutant as a Promising Vaccine Against Toxoplasmosis in Mice. Microbial Biotechnology. https://doi.org/10.1111/1751-7915.70143
Vancouver
Luo Y, He M, Yang S, Qian J, He Z, Xu J, et al. Toxoplasma gondii C2 Domain Protein Deletion Mutant as a Promising Vaccine Against Toxoplasmosis in Mice. Microbial Biotechnology. 2025. doi:10.1111/1751-7915.70143
BibTeX
@article{Luo2025,
author = {Luo, Yifan and He, Mingfeng and Yang, Shengqiang and Qian, Jiahui and He, Zhengming and Xu, Jiayin and Guo, Liyu and Xiao, Siyu and Fang, Rui},
title = {Toxoplasma gondii C2 Domain Protein Deletion Mutant as a Promising Vaccine Against Toxoplasmosis in Mice},
journal = {Microbial Biotechnology},
year = {2025},
doi = {10.1111/1751-7915.70143}
}
EUVIMED